Welcome to our dedicated page for Immucell news (Ticker: ICCC), a resource for investors and traders seeking the latest updates and insights on Immucell stock.
ImmuCell Corporation (Nasdaq: ICCC) is an animal health company that develops, manufactures and markets scientifically proven and practical products to improve the health and productivity of dairy and beef cattle. News about ImmuCell often centers on sales performance for its First Defense® product line, strategic decisions regarding its Re-Tain® mastitis treatment candidate, and updates on manufacturing capacity and financing.
Investors following ICCC news can expect regular preliminary, unaudited product sales updates shortly after quarter-end, followed by detailed unaudited financial results releases. These announcements typically include commentary on product sales trends for First Defense®, including Tri-Shield® and Dual-Force® variants, domestic and international sales mix, gross margin performance, and the impact of prior production backlogs and inventory rebuilding.
Company news also covers strategic shifts, such as ImmuCell’s decision to focus resources on expanding the First Defense® franchise after receiving an FDA Incomplete Letter for the Re-Tain® New Animal Drug Application. Releases describe plans to increase the First Defense® sales force, expand manufacturing capacity, repurpose assets, and complete investigational Re-Tain® studies to support potential licensing or partnership opportunities.
Additional ICCC news items include leadership changes, such as the selection and onboarding of a new President and CEO, bank debt refinancing transactions, extensions of credit facilities, and details of conference calls with investors. For readers tracking ICCC, this news feed provides a centralized view of operational updates, product development milestones, capital structure developments and management commentary related to ImmuCell’s cattle health business.
ImmuCell Corporation (Nasdaq: ICCC) reported a strong performance for the year ended December 31, 2021, with product sales increasing by 25% to $19.2 million compared to 2020. In Q4 alone, sales surged by 45% to $5.4 million. The company's gross margin improved to 47% for Q4 and 45% for the year. Net operating income shifted to a gain of $257,000, contrasting with a $1.4 million loss in 2020. Cash and equivalents rose to $10.2 million. A significant FDA submission regarding Re-Tain is expected to impact future market launch plans.
ImmuCell Corporation (Nasdaq: ICCC) plans to announce its unaudited financial results for Q4 and the year ended December 31, 2021, on February 22, 2022. A conference call will be held on February 23, 2022, at 9:00 AM ET, where executives will discuss production capacity investments for the First Defense product line and insights regarding the upcoming launch of Re-Tain.
The Annual Report on Form 10-K is expected to be filed by March 30, 2022. Stakeholders are encouraged to view the updated corporate presentation on the company's website following the financial results announcement.
ImmuCell Corporation (Nasdaq: ICCC) reported preliminary unaudited sales of $19.2 million for 2021, marking a 25% increase from 2020's $15.3 million. The fourth quarter saw sales of $5.4 million, a 45% rise from $3.7 million in the previous year. The company attributes this growth to strategic investments in expanding manufacturing capacity for its First Defense® product, with plans for further investment of $1.8 million to enhance production capabilities to approximately $35 million. ImmuCell is also progressing on its Re-Tain® drug application to the FDA.
ImmuCell Corporation (Nasdaq: ICCC) reported a net income of $148,000 for Q3 2021, a significant turnaround from the net loss of ($323,000) in Q3 2020. Total product sales rose 38% to $5.2 million, while nine-month sales increased 19% to $13.8 million. The company achieved a gross margin of 47% in Q3 2021 and improved EBITDA to approximately $852,000. Cash reserves grew to $10.5 million as of September 30, 2021, up from $7.9 million at year-end 2020. ImmuCell plans to submit another Technical Section to the FDA for its product Re-Tain® by year-end 2021.
ImmuCell Corporation (Nasdaq: ICCC), a company focused on improving the health of dairy and beef cattle, will report unaudited financial results for Q3 and the nine-month period ending September 30, 2021, after market close on November 15, 2021. A conference call will be held on November 16, 2021, at 9:00 AM ET to discuss these results. The Quarterly Report on Form 10-Q will be filed concurrently. Details about their products, including First Defense and Re-Tain, are available on their website.
ImmuCell Corporation (Nasdaq: ICCC) reported preliminary, unaudited sales results for Q3 2021, showcasing a significant increase in total sales. For the three-month period ending September 30, sales reached $5.2 million, a 38% increase compared to $3.7 million in Q3 2020. Year-to-date sales also rose to $13.8 million, up 19% from $11.6 million year-over-year. The company's production capacity is expanding, with plans to increase annual capacity from $16.5 million to $23 million. This growth is attributed to fulfilling backlog orders and improved production capabilities.
ImmuCell Corporation (Nasdaq: ICCC) has announced the hiring of Dr. Raffael Lichdi as its new Commercial Research & Technical Services Veterinarian. Dr. Lichdi, an experienced veterinarian with a background in large dairy consulting and animal health companies, is expected to enhance the company's market position, particularly for its subclinical mastitis treatment, Re-Tain®. This product aims to treat dairy cows without the need for milk discards and is pending FDA approval. The company is also addressing a backlog in its First Defense® product line by expanding production capacity.
ImmuCell Corporation (Nasdaq: ICCC) announced the FDA issued a Technical Section Incomplete Letter regarding its CMC submission for Re-Tain®, aimed at treating subclinical mastitis in dairy cows. This letter pertains to manufacturing requirements for the drug substance and product. The company plans to resubmit the CMC section in Q4 2021, aiming for a New Animal Drug Approval by Q3 2022. The previous FDA letters had covered four other major sections necessary for product approval.
ImmuCell Corporation (Nasdaq: ICCC) reported a net income of $141,000 for Q2 2021, a significant turnaround from a net loss of $766,000 in Q2 2020. Total product sales surged by 53% to $4.5 million compared to $2.9 million in the prior year. Despite experiencing delays in production capacity expansion, the company managed to reduce its backlog of First Defense® orders and increased its annualized production output to approximately $18.2 million. Gross margins improved to 46% in Q2 2021, up from 43% in the same period last year. Cash and equivalents rose to $10.7 million.
ImmuCell Corporation (Nasdaq: ICCC) plans to announce its unaudited financial results for Q2 2021 on August 12, 2021, after market close. A conference call to discuss these results is scheduled for August 13, 2021, at 9:00 AM ET. Investors will have access to the financial report via the company’s website post-release. ImmuCell focuses on developing products to enhance the health of dairy and beef cattle, including First Defense® for calf immunity and Re-Tain® for mastitis treatment.